Boston Scientific

Boston Scientific Hits $2.1 Billion in Q3 Sales

By MedTech Intelligence Staff
Boston Scientific

The company is performing well across all business units and geographies.

Boston Scientific Corp. is enjoying strong revenue growth in all of its business segments. Yesterday the company reported its 2016 third quarter sales, which reached $2.1 billion, thanks to an 11% increase compared to the prior year period.

According to a company release, Boston Scientific reported the following growth:

Business Units

  • MedSurg: 15%
  • Cardiovascular: 13%
  • Rhythm Management: 4%


  • United States: 11%
  • Europe: 6%
  • Asia-Pacific, Middle East and Africa: 20%
  • Emerging markets: 10%

Other noteworthy developments this quarter include the agreement to acquire EndoChoice Holdings, Inc., a company that provides products to treat gastrointestinal conditions; FDA approval of its EMBLEM MRI Subcutaneous Implantable Defibrillator; CE Mark of the LOTUS Edge Valve System (TAVR); and a $25-million in vestment in VENITI, Inc., a manufacturer of stents for chronic venous insufficiency.

Related Articles

About The Author

MedTech Intelligence